Brainomix Secures $20M Series C Funding to Revolutionize Stroke Imaging and Patient Care

Brainomix is thrilled to announce a milestone funding round of $20 million that will accelerate our mission of turning ordinary scans into extraordinary insights. Since our 2010 spin-out from the University of Oxford, we have passionately advanced the field of medical imaging, empowering neurologists, interventionalists, and radiologists with award-winning, AI-powered imaging biomarkers and software solutions. Our flagship product, Brainomix 360, enhances stroke imaging interpretation by delivering the right insights to the right people at the right time—ensuring every patient receives expert-level care, no matter where they are. This significant investment is a testament to the trust that investors and industry leaders have in our vision and innovations. With the new funding, Brainomix will further refine and scale our smart imaging platform, accelerating research and development initiatives to enhance accuracy and operational efficiency across stroke and lung care pathways. Our commitment is rooted in creating impactful, scalable, and smart solutions that integrate seamlessly into existing radiology workflows, ultimately enabling physicians worldwide to make critical, life-saving decisions faster and with greater confidence. As we build on our legacy of transforming medical imaging with cutting-edge technology, these funds will also support expansion into new markets and further development of our suite of AI algorithms. We are excited to continue our journey of innovation, pushing the boundaries of stroke imaging interpretation to ensure that every patient benefits from expert-level, data-driven care. Reach out today to learn why Brainomix remains an essential partner not only for healthcare professionals but also for every patient and institution committed to advancing medical care.